JP2002281984A - 抗ＩｇＥワクチン - Google Patents

抗ＩｇＥワクチン

Info

Publication number
JP2002281984A
JP2002281984A JP2001261760A JP2001261760A JP2002281984A JP 2002281984 A JP2002281984 A JP 2002281984A JP 2001261760 A JP2001261760 A JP 2001261760A JP 2001261760 A JP2001261760 A JP 2001261760A JP 2002281984 A JP2002281984 A JP 2002281984A
Authority
JP
Japan
Prior art keywords
seq
ige
amino acid
antigenic
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001261760A
Other languages
English (en)
Japanese (ja)
Inventor
Mohamad A Morsey
モハマド・アリ・モーシー
Michael George Sheppard
マイケル・ジョージ・シェパード
David W Wheeler
デーヴィッド・ウォルター・ホイーラー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of JP2002281984A publication Critical patent/JP2002281984A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/805—Drug, bio-affecting and body treating compositions involving IgE or IgD
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2001261760A 2000-08-30 2001-08-30 抗ＩｇＥワクチン Pending JP2002281984A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22898900P 2000-08-30 2000-08-30
US60/228989 2000-08-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2004244935A Division JP2005043374A (ja) 2000-08-30 2004-08-25 抗ＩｇＥワクチン
JP2004338711A Division JP2005102701A (ja) 2000-08-30 2004-11-24 抗ＩｇＥワクチン

Publications (1)

Publication Number Publication Date
JP2002281984A true JP2002281984A (ja) 2002-10-02

Family

ID=22859366

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2001261760A Pending JP2002281984A (ja) 2000-08-30 2001-08-30 抗ＩｇＥワクチン
JP2004244935A Pending JP2005043374A (ja) 2000-08-30 2004-08-25 抗ＩｇＥワクチン
JP2004338711A Pending JP2005102701A (ja) 2000-08-30 2004-11-24 抗ＩｇＥワクチン
JP2012080895A Pending JP2012161322A (ja) 2000-08-30 2012-03-30 抗ＩｇＥワクチン
JP2012232974A Pending JP2013056904A (ja) 2000-08-30 2012-10-22 抗ＩｇＥワクチン

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2004244935A Pending JP2005043374A (ja) 2000-08-30 2004-08-25 抗ＩｇＥワクチン
JP2004338711A Pending JP2005102701A (ja) 2000-08-30 2004-11-24 抗ＩｇＥワクチン
JP2012080895A Pending JP2012161322A (ja) 2000-08-30 2012-03-30 抗ＩｇＥワクチン
JP2012232974A Pending JP2013056904A (ja) 2000-08-30 2012-10-22 抗ＩｇＥワクチン

Country Status (4)

Country Link
US (5) US6887472B2 (enExample)
EP (5) EP1195161A3 (enExample)
JP (5) JP2002281984A (enExample)
CA (5) CA2674837C (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012511322A (ja) * 2008-12-09 2012-05-24 ファイザー バクシーンズ エルエルシー ＩｇＥＣＨ３ペプチドワクチン
WO2013191166A1 (ja) * 2012-06-18 2013-12-27 日本全薬工業株式会社 IgEペプチドワクチン
WO2015190555A1 (ja) * 2014-06-11 2015-12-17 国立研究開発法人理化学研究所 多重同種抗原ペプチド

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1195161A3 (en) * 2000-08-30 2002-07-24 Pfizer Products Inc. Anti-IgE vaccines
EP2687593A1 (en) * 2001-05-15 2014-01-22 Ortho-McNeil Pharmaceutical, Inc. Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
JP2003047482A (ja) * 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
ATE414540T1 (de) * 2002-09-05 2008-12-15 Resistentia Pharmaceuticals Ab Impfstoffe gegen allergien
US20070178082A1 (en) * 2002-11-08 2007-08-02 Ablynx N.V. Stabilized single domain antibodies
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
WO2004041862A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
KR20070008578A (ko) 2004-02-02 2007-01-17 타녹스 인코퍼레이티드 신규한 ＩｇＥ 에피토프의 확인
JP4520923B2 (ja) * 2005-09-28 2010-08-11 本田技研工業株式会社 エンジン始動装置
JP2007172129A (ja) * 2005-12-20 2007-07-05 Sony Corp 不揮発性メモリアクセス制御装置および不揮発性メモリ制御システム
AU2013204233B2 (en) * 2008-12-09 2015-06-25 Pfizer Vaccines Llc IgE CH3 peptide vaccine
RU2015109110A (ru) * 2009-02-25 2015-07-20 Академиа Синика Применение семх пептидов для индукции иммунного ответа на мембрансвязанный ige (mige) на человеческих в лимфоцитах
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
KR101163472B1 (ko) * 2010-06-08 2012-07-18 기아자동차주식회사 자동차의 오프닝 웨더스트립 고정구조
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
CN104603150A (zh) 2012-04-20 2015-05-06 中央研究院 与CH4和CεmX结构域之间的连接处结合的抗mIgE抗体
CN102660569B (zh) * 2012-04-21 2013-11-06 大连理工大学 一种重组人IgE受体蛋白的制备方法及应用
CA2982213C (en) * 2015-04-09 2022-10-18 Cornell University Gene therapy to prevent reactions to allergens
IL277911B2 (en) 2017-10-31 2025-07-01 Oneness Biotech Co Ltd Treating ige-mediated allergic diseases
US11857623B2 (en) * 2020-08-07 2024-01-02 King Abdulaziz University Pan-antiallergy vaccine
US20260035484A1 (en) * 2021-10-29 2026-02-05 Longbio Pharma (Suzhou) Co., Ltd. Isolated antigen binding protein and use thereof
CN115873867B (zh) * 2022-09-28 2023-06-23 云南省农业科学院农业环境资源研究所 一种抗稻瘟病基因Pi69及其编码蛋白与应用
CN120271714A (zh) * 2022-12-07 2025-07-08 南开大学 一种针对IgE的抗体或其抗原结合片段以及Fc变体
CN118878689B (zh) * 2024-08-28 2025-03-28 上海索莱宝生化科技有限公司 抗猪IgG抗体及其应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
JPS5668615A (en) * 1979-11-09 1981-06-09 Eisai Co Ltd Ricin-containing agent for immunological enhancement
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
GB8616166D0 (en) * 1986-07-02 1986-08-06 Research Corp Ltd Polypeptide competitor
JPS63225397A (ja) 1986-10-03 1988-09-20 Dainippon Pharmaceut Co Ltd 抗アレルギー作用を有する新規ペプチド
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
WO1992006180A1 (en) 1990-10-01 1992-04-16 University Of Connecticut Targeting viruses and cells for selective internalization by cells
CA2103064A1 (en) 1991-05-14 1992-11-15 George Y. Wu Targeted delivery of genes encoding immunogenic proteins
AU657345B2 (en) 1991-05-24 1995-03-09 Northwestern University Method of using substance P to treat allergy
WO1992022635A1 (en) 1991-06-05 1992-12-23 University Of Connecticut Targeted delivery of genes encoding secretory proteins
US5965709A (en) * 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
SE9102808L (sv) 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
WO1993014188A1 (en) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus
WO1993020221A1 (en) 1992-04-03 1993-10-14 Young Alexander T Gene therapy using targeted viral vectors
WO1994008598A1 (en) 1992-10-09 1994-04-28 Advanced Tissue Sciences, Inc. Liver reserve cells
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
GB9324013D0 (en) * 1993-11-22 1994-01-12 3I Res Expl Ltd Polypeptides
FR2715304B1 (fr) * 1994-01-26 1996-04-26 Merieux Serums Vaccins Pasteur Vaccin anti-allergique.
US5629415A (en) * 1994-11-09 1997-05-13 Merck & Co., Inc. DNA encoding canine immunoglobulin E
JPH09169795A (ja) * 1995-12-22 1997-06-30 Hitachi Chem Co Ltd イヌ免疫グロブリンｅペプチド断片、それをコードするｄｎａ、そのｄｎａを含む組換えベクター、その組換えベクターを含む形質転換体及び抗イヌ免疫グロブリンｅ抗体の製造法
WO1997030156A2 (en) 1996-02-14 1997-08-21 Idexx Laboratories, Inc. NUCLEOTIDES AND PEPTIDES CORRESPONDING TO THE CANINE IgE HEAVY CHAIN CONSTANT REGION AND RELATED METHODS
CN1174998C (zh) 1996-03-01 2004-11-10 诺瓦提斯公司 用于预防和治疗过敏的肽免疫原
ES2165626T3 (es) 1996-08-30 2002-03-16 Exxonmobil Chem Patents Inc Reactor y procedimiento en lecho fluidizado.
WO1998024808A2 (en) * 1996-12-06 1998-06-11 THE UNITED STATES OF AMERICA represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH INHIBITION OF IgE-MEDIATED ALLERGIES BY A HUMAN IgE-DERIVED OLIGOPEPTIDE
ES2234180T3 (es) * 1998-04-09 2005-06-16 Idexx Laboratories, Inc. Proteinas de fijacion especifica para el tratamiento de la alergia canina.
US6734287B1 (en) * 1998-04-09 2004-05-11 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
TWI229679B (en) * 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
PL198236B1 (pl) * 1998-06-24 2008-06-30 Alk Abello As Sposób określania działania swoistego szczepienia przeciw alergii oraz sposób określania stanu immunologicznego osobnika alergicznego
GB9822763D0 (en) * 1998-10-20 1998-12-16 Univ Sheffield Immunoglobin variant
US6913749B2 (en) * 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
CN1202125C (zh) * 1998-11-12 2005-05-18 卫生部上海生物制品研究所 肽免疫原、用其制成的治疗变态反应的疫苗及其制备方法
EP1195161A3 (en) * 2000-08-30 2002-07-24 Pfizer Products Inc. Anti-IgE vaccines
JP2003047482A (ja) 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012511322A (ja) * 2008-12-09 2012-05-24 ファイザー バクシーンズ エルエルシー ＩｇＥＣＨ３ペプチドワクチン
JP2014012009A (ja) * 2008-12-09 2014-01-23 Pfizer Vaccines Llc ＩｇＥＣＨ３ペプチドワクチン
WO2013191166A1 (ja) * 2012-06-18 2013-12-27 日本全薬工業株式会社 IgEペプチドワクチン
JPWO2013191166A1 (ja) * 2012-06-18 2016-05-26 日本全薬工業株式会社 ＩｇＥペプチドワクチン
US9657071B2 (en) 2012-06-18 2017-05-23 Nippon Zenyaku Kogyo Co., Ltd. IgE peptide vaccine
WO2015190555A1 (ja) * 2014-06-11 2015-12-17 国立研究開発法人理化学研究所 多重同種抗原ペプチド
JPWO2015190555A1 (ja) * 2014-06-11 2017-04-20 国立研究開発法人理化学研究所 多重同種抗原ペプチド
US10428112B2 (en) 2014-06-11 2019-10-01 Riken Multiplexed same type-antigenic peptide

Also Published As

Publication number Publication date
EP2065052A2 (en) 2009-06-03
EP2361635A3 (en) 2011-09-14
US20040146504A1 (en) 2004-07-29
EP2065052A3 (en) 2009-08-19
JP2005043374A (ja) 2005-02-17
US20100113361A1 (en) 2010-05-06
US7897151B2 (en) 2011-03-01
CA2674888A1 (en) 2002-02-28
EP1195161A2 (en) 2002-04-10
JP2005102701A (ja) 2005-04-21
JP2013056904A (ja) 2013-03-28
JP2012161322A (ja) 2012-08-30
CA2674838C (en) 2014-02-18
EP1967206A3 (en) 2009-01-07
US8273356B2 (en) 2012-09-25
CA2674885C (en) 2013-02-26
CA2674837C (en) 2013-02-26
CA2674885A1 (en) 2002-02-28
EP1967205A2 (en) 2008-09-10
US20120321651A1 (en) 2012-12-20
EP1967205A3 (en) 2009-01-07
EP1967206B1 (en) 2012-10-10
CA2356124A1 (en) 2002-02-28
CA2674838A1 (en) 2002-02-28
EP1967206A2 (en) 2008-09-10
US6887472B2 (en) 2005-05-03
EP2361635A2 (en) 2011-08-31
CA2674837A1 (en) 2002-02-28
US20060062782A1 (en) 2006-03-23
EP1195161A3 (en) 2002-07-24
EP1967205B1 (en) 2012-10-10
US20020064525A1 (en) 2002-05-30

Similar Documents

Publication Publication Date Title
JP2002281984A (ja) 抗ＩｇＥワクチン
CN1771338B (zh) 高亲和力抗人类IgE抗体
JP2003520828A (ja) Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
BRPI0821168B1 (pt) Anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de ditoanticorpo ou fragmento, e, hibridoma
US20080193439A1 (en) Non-Anaphylactogenic IgE Fusion Proteins
JP4538192B2 (ja) 免疫疾患を治療するための融合分子及び方法
KR101365375B1 (ko) 신규한 ＩｇＥ 에피토프의 확인
US6113903A (en) Peptides and methods against diabetes
EP1131354A1 (en) Contraceptive antibody vaccines
TW201623328A (zh) Ｅｐｓｉｇａｍ融合蛋白質

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20040825

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20040830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20050607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050905

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20051017

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20051111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071106

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071109